1
|
Gillet JP, Calcagno AM, Varma S, Marino M,
Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al:
Redefining the relevance of established cancer cell lines to the
study of mechanisms of clinical anti-cancer drug resistance. Proc
Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Gazdar AF, Gao B and Minna JD: Lung cancer
cell lines: Useless artifacts or invaluable tools for medical
science? Lung Cancer. 68:309–318. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Nugoli M, Chuchana P, Vendrell J, Orsetti
B, Ursule L, Nguyen C, Birnbaum D, Douzery EJ, Cohen P and Theillet
C: Genetic variability in MCF-7 sublines: Evidence of rapid genomic
and RNA expression profile modifications. BMC Cancer. 3:132003.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Inoue A, Yokomori K, Tanabe H, Mizusawa H,
Sofuni T, Hayashi Y, Tsuchida Y and Shimatake H: Extensive genetic
heterogeneity in the neuroblastoma cell line NB(TU)1. Int J Cancer.
72:1070–1077. 1997. View Article : Google Scholar : PubMed/NCBI
|
5
|
Treanor LM, Zhou S, Janke L, Churchman ML,
Ma Z, Lu T, Chen SC, Mullighan CG and Sorrentino BP: Interleukin-7
receptor mutants initiate early T cell precursor leukemia in murine
thymocyte progenitors with multipotent potential. J Exp Med.
211:701–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hait WN: Anticancer drug development: The
grand challenges. Nat Rev Drug Discov. 9:253–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hutchinson L and Kirk R: High drug
attrition rates - where are we going wrong? Nat Rev Clin Oncol.
8:189–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Robinson JT, Thorvaldsdóttir H, Winckler
W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative
genomics viewer. Nat Biotechnol. 29:24–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Srivastava BI, Minowada J and Moore GE:
High terminal deoxynucleotidyl transferase activity in a new T-cell
line (RPMI 8402) of acute lymphoblastic leukemia origin. J Natl
Cancer Inst. 55:11–14. 1975.PubMed/NCBI
|
10
|
Gu Y, Lu K, Yang G, Cen Z, Yu L, Lin L,
Hao J, Yang Z, Peng J, Cui S and Huang J: Mutation spectrum of six
genes in Chinese phenylketonuria patients obtained through
next-generation sequencing. PLoS One. 9:e941002014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Cai X, Sheng J, Tang C, Nandakumar V, Ye
H, Ji H, Tang H, Qin Y, Guan H, Lou F, et al: Frequent mutations in
EGFR, KRAS and TP53 genes in human lung cancer tumors detected by
ion torrent DNA sequencing. PLoS One. 9:e952282014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bai X, Zhang E, Ye H, Nandakumar V, Wang
Z, Chen L, Tang C, Li J, Li H, Zhang W, et al: PIK3CA and TP53 gene
mutations in human breast cancer tumors frequently detected by ion
torrent DNA sequencing. PLoS One. 9:e993062014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Mitra A, Mishra L and Li S: Technologies
for deriving primary tumor cells for use in personalized cancer
therapy. Trends Biotechnol. 31:347–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Marjanovic ND, Weinberg RA and Chaffer CL:
Cell plasticity and heterogeneity in cancer. Clin Chem. 59:168–179.
2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Gebhart E, Thoma K, Verdorfer I, Drexler
HG and Efferth T: Genomic imbalances in T-cell acute lymphoblastic
leukemia cell lines. Int J Oncol. 21:887–894. 2002.PubMed/NCBI
|
17
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
18
|
Sottoriva A, Spiteri I, Piccirillo SG,
Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C and Tavaré
S: Intratumor heterogeneity in human glioblastoma reflects cancer
evolutionary dynamics. Proc Natl Acad Sci USA. 110:4009–4014. 2013.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Mullighan CG: The molecular genetic makeup
of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ
Program. 2012:389–396. 2012.PubMed/NCBI
|